Pupillometry Guided Remifentanil Administration In Pediatric Anesthesia
A Prospective Randomized Study Evaluating Pupillometry Guided Remifentanil Administration in Pediatric Anesthesia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Geneva, Switzerland, 1206
- Geneva Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Children scheduled for a surgery lasting more than 90 minutes.
Exclusion Criteria:
- Contraindication to sevoflurane, to remifentanil or to morphine.
- Peripheral or central nerve block during and after surgery.
- Ophthalmological disease.
- Peroperative position with no acess to the head.
- Chronic use of medication interfering with pupillary diameter.
- Ambulatory surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Standard practice
Remifentanil infusion guided by usual clinical signs (heart rate, blood pressure). Pupillometry blindly recorded. Anesthesia maintenance with sevoflurane. |
Administered to maintain a Bispectral Index between 40 and 60
|
|
Experimental: Pupillometry
Remifentanil infusion guided by changes in pupillary diameter.
Anesthesia maintenance with sevoflurane.
|
Administered to maintain a Bispectral Index between 40 and 60
Pupillary diameter measured every 5 minutes
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
peroperative remifentanil consumption
Time Frame: duration of surgery
|
duration of surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Morphine consumption
Time Frame: during the 24 hour post operative period
|
during the 24 hour post operative period
|
|
|
Incidence of morphine side effects
Time Frame: during the 24 hour post operative period
|
Sedation, nausea, vomiting, pruritus, urinary retention
|
during the 24 hour post operative period
|
|
Pain scoring (verbal numerical scale)
Time Frame: during the 24 hour post operative period
|
during the 24 hour post operative period
|
|
|
Pain scoring (questionnaire)
Time Frame: one month post-operatively
|
one month post-operatively
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Walid Habre, MD, PhD, University of Geneva
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Pupilloped
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.